Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review (Q36186039)

From Wikidata

Jump to navigation Jump to search

scientific article published in 2016

Language	Label	Description	Also known as
English	Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review	scientific article published in 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

3 references

24 March 2019

25 April 2019

25 January 2021

Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

hyperprolactinemia

2 references

24 March 2019

25 April 2019

2 references

24 March 2019

25 April 2019

1 reference

25 January 2021

Kristian Thorlund

8

object named as

Kristian Thorlund

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Edward J. Mills

7

object named as

Edward J Mills

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

author name string

Eric Druyts

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Michael J Zoratti

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kabirraaj Toor

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Ping Wu

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Salmaan Kanji

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kiran Rabheru

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 November 2016

4 references

Europe PubMed Central

PMC publication ID

12 August 2017

24 March 2019

25 April 2019

25 January 2021

4 references

Europe PubMed Central

PMC publication ID

12 August 2017

24 March 2019

25 April 2019

25 January 2021

16

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

181

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

copyright license

Creative Commons Attribution 4.0 International

3 references

Europe PubMed Central

24 March 2019

Europe PubMed Central

25 April 2019

Europe PubMed Central

25 January 2021

copyright status

0 references

on focus list of Wikimedia project

0 references

The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Antipsychotic-induced hyperprolactinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

A roadmap to key pharmacologic principles in using antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

The effect of atypical antipsychotic agents on prolactin levels in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

1 October 2017

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

2 July 2018

A study of serum prolactin levels in schizophrenia: comparison of males and females

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

2 July 2018

Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Ten years of antipsychotic prescribing to children: a Canadian population-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Prolactin levels during long-term risperidone treatment in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Serum prolactin levels in humans from birth to adult life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5101725

23 September 2018

Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response

1 reference

https://pubmed.ncbi.nlm.nih.gov/27825323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/27825323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/27825323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/27825323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12887-016-0710-Y

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36186039&oldid=2198312042"